Interpretation of long-term survival data from MONARCH 3. Letter to the Editor regarding "Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3" by M. P. Goetz et al.
A D SherryT A LinZ R McCawE B LudmirPublished in: Annals of oncology : official journal of the European Society for Medical Oncology (2024)